Stay up-to-date on the advancing field of HCT with short summaries and links to the most relevant published research.
Younger matched unrelated donors may reduce relapse risk after allogeneic HCT compared to using older matched sibling donors
Allogeneic HCT may be a better option for older patients with AML than conventional consolidation therapy
Sequential conditioning may offer comparable remission and survival rates to intensive induction chemotherapy pre-allogeneic HCT for relapsed refractory AML patients
Structural racism variable accounts for almost all racial and ethnic disparity AML survival
Maakaron JE, et al. – Research published in Bone Marrow Transplantation suggests that age alone should not be a deciding factor when determining candidacy for transplant in adult patients with acute myeloid leukemia (AML), and transplant should be considered a standard of care option for patients of all ages with AML in first complete remission. This study showed that all age groups reached comparable 3-year overall survival, and differences between younger and older groups were better explained by comorbidities and other factors than age.
Rapid donor identification improves survival in high-risk first-remission patients with Acute Myeloid Leukemia
John M. Pagel, MD, PhD, Megan Othus, PhD, et al – Barriers to human leukocyte antigen (HLA) typing and cytogenetic testing can significantly impact the overall survival of patients newly diagnosed with acute myeloid leukemia (AML). In this landmark study, a concerted effort to address those issues and streamline the initiation of donor identification and referral for hematopoietic cell transplant (HCT) consultation in early disease state led to a higher CR1 transplantation rate and improved 2-year overall survival.
Comparable long-term outcomes in matched unrelated and sibling donor HCT in older patients with AML
Shimoni A, et al., Biol Blood Marrow Transplant – In an analysis of 1134 patients age 50 or older with acute myeloid leukemia (AML), two-year hematopoietic cell transplant (HCT) survivors experienced comparable 10-year leukemia-free survival (LFS) and overall survival (OS) with matched sibling or unre-lated donors.
Subscribe to E-News
Receive new research summaries monthly.